DNA Methylation Detection Technology Market Size, Share and Trends Analysis, By Product (Instruments, Software, and Consumables), By Technology (PCR, Sequencing, Microarray and Others), By Application, By End-Use, and By Region, Forecast 2025-2032

Global DNA Methylation Detection Technology Market Overview and Key Insights:

The global DNA methylation detection technology market size reached USD 2,880.2 Million in 2024 and is expected to register a revenue CAGR of 17.5% during the forecast period. DNA methylation, which occurs most commonly at the C5 position of cytosines in CpG dinucleotides, is critical in numerous biological processes, including gene expression, embryonic development, cellular proliferation, differentiation, and chromosome integrity.

Market Drivers:

Increasing prevalence of cancer and epigenetic disorders is a key driver of revenue growth in the DNA methylation detection technology market. According to the International Agency for Research on Cancer (IARC), in 2022, there are expected to be 20 million new cancer diagnoses and 9.7 million fatalities. The expected number of people who survived 5 years after a cancer diagnosis was 53.5 million. Cancer affects around one in every five persons in their lifetime, with one in every nine men and one in every twelve women dying from it. Lung cancer was the most frequent cancer in the globe, accounting for 2.5 million new cases, or 12.4% of all new cases. Female breast cancer came in second (2.3 million cases, 11.6%), followed by colorectal cancer (1.9 million, 9.6%), prostate cancer (1.5 million, 7.3%), and stomach cancer (970,000, 4.9%).

Technological advancement of DNA methylation detection technology is driving the demand for DNA methylation detection technology market. On June 2023, Oxford Nanopore has released an all-context methylation model that allows for real-time, high-accuracy epigenetic insights. It incorporates the capabilities of its flagship machine learning tool into the core basecaller and expands its ability to detect methylation in non-human DNA, such as plants and bacteria. This will speed up research, allowing for a more thorough investigation of disease processes, biomarkers, evolutionary dynamics, and the interaction between genes and the environment.

Market Opportunity:

Development of point-of-care testing acts as an opportunity for the DNA methylation detection technology market. DNA methylation has been intensively studied in recent years, not least because of its documented association with a variety of illnesses. Advances in analytical methods can significantly raise the importance of DNA methylation investigations in clinical practice and scientific research.  On-chip molecular analysis has attracted a lot of interest for its portability, high throughput, low cost, and great efficiency. In recent years, the use of new microfluidic chips for DNA methylation analysis has been widely documented, with clear advantages over traditional approaches.

Recent Trends:

Recent trends include the increasing clinical applications, integration with personalized medicine and Artificial Intelligence (AI).

Artificial intelligence (AI) and machine learning (ML) technologies, particularly deep learning (DL), have distinct benefits in the processing of the massive troves of biological data generated by omics studies such as DNA-methylation. AI can predict disease outbreaks and provide individualized health monitoring systems. AI may analyze patient data, including activity levels and vital signs, to deliver individualized recommendations for health improvement and illness prevention.

On January 2024, FOXO Technologies Inc., a pioneer in the commercialization of epigenetic biomarker technology, announced that it has formalized its collaboration with KR8.ai Inc. and obtained an exclusive license to KR8’s AI-based software to support the development and commercial launch of its new health and wellness offering, the VITHAR AI Health Coach.

Restraints & Challenges:

Technical challenges in methylation analysis and data complexity and interpretation pose a significant hurdle to the implementation of DNA methylation detection technology market. One of the issues in DNA methylation research is that, while each organism has only one genome, there can be hundreds of epigenomes because DNA methylation varies with cell type, throughout development or disease processes, and occasionally in reaction to the environment. Furthermore, the computational analysis of DNA methylation sequencing data obtained by various experimental procedures can be difficult, particularly for scientists with little experience in this area of data processing.

Product Segment Insights and Analysis:

Based on the product, the DNA methylation detection technology market is segmented into instruments, software, and consumables.

Consumables segment contributed largest share in 2024. Epigenetic processes are anticipated to play a major role in regulating metabolism and body weight via gene-nutrient interactions. Researchers and clinicians prefer pre-assembled kits and the growing adoption of NGS platforms, the demand for consumables also increases. Consumables are integral to the success of DNA methylation detection workflows, offering precision, reliability, and efficiency.

On May 2024, QIAGEN has launched its QIAseq Multimodal DNA/RNA Library Kit. The new kit allows for the seamless creation of DNA and RNA libraries for next-generation sequencing (NGS), including whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment using hybrid-capture from a single sample. The kit provides a simplified and efficient method for generating WGS and WTS libraries from a single sample by combining chemistry optimized for DNA and RNA.

Instruments segment is expected to have the highest growth rate throughout the forecasted period. These platforms facilitate high-throughput, precise and cost-effective methylation analysis, thereby addressing the demands of research, clinical diagnostics, and therapeutic applications. Improved patient outcomes and precision medicine approaches drive platform adoption in clinical diagnostics. On June 2024, Epigenica, a start-up that developed the first multiplex, high-throughput tools for epigenomic research, introduced its EpiFinder Platform, which includes patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology, as well as EpiFinder Genome, which allows for comprehensive genome-wide profiling. EpiFinder Genome, the company’s flagship product and the first commercial kit of its kind, simultaneously targets up to eight markers in up to 24 samples or independent replicates, producing quantitative data for in-depth insights into biomedical research, drug discovery and development, diagnostics, and precision medicine.

Technology Segment Insights and Analysis:

Based on the technology, the DNA methylation detection technology market is segmented into microarray, Polymerase Chain Reaction (PCR), sequencing, and others.

Microarray segment contributed largest share in 2024. Microarray-based methylation profiling has emerged as an important method for improving diagnosis and identifying new tumour subtypes, notably in central nervous system cancers. Methylation arrays allow for quantitative interrogation of specific methylation sites across the genome, resulting in high throughput and low cost per sample. Array-based methylation studies can provide important insights into gene expression control.

Microarrays are advantageous for methylation investigations because they may target methylated or potentially methylated regions. CpG island arrays, for example, aim to capture all known CpG islands. Promoter arrays are also quite common; they normally include all the reference promoters for the species of interest (human, mouse, or rat). For example, the Illumina 450k infinium methylation beadchip is one of the most often utilized chips in human methylation studies. It includes 96% of CpG islands, over 99% of promoters, non-CpG methylation sites, and miRNA promoters.

Sequencing segment accounted for the fastest growth rate during the forecasted period. DNA methylation sequencing is a recent technology that uses bisulfite conversion to distinguish methylated from unmethylated cytosines. Bisulfite genomic sequencing is recognized as the gold-standard methodology for detecting DNA methylation since it provides a qualitative, quantitative, and efficient method for identifying 5-methylcytosine at single base-pair resolution.

On November 2024, Wasatch Biolabs (WBL), a disruptive R&D and high-throughput clinical laboratory, has announced a collaboration with Oxford Nanopore Technologies, a company that provides a new generation of nanopore-based molecular sensing technology, to create a Direct Whole Methylome Sequencing product that addresses key limitations of traditional bisulfite sequencing and methylation microarrays. This collaboration aims to expand Wasatch BioLab’s existing unique methylation tests and develop market-leading solutions to accelerate innovation in genomic and epigenomic analysis, accelerating discoveries in research and clinical applications.

Application Segment Insights and Analysis:

Based on the application, the DNA methylation detection technology market is segmented into clinical research, diagnostics, gene therapy, and others.

Diagnostics segment contributed largest share in 2024. Epigenetics research has become a critical tool for identifying gene-environment interactions that influence risk exposure, treatment benefit, and disease development. According to the American Cancer Society, over 2 million additional cancer cases are predicted to be identified in the United States by 2024. In 2024, the US is anticipated to have 611,720 cancer-related fatalities, which equates to around 1,680 each day. Cancer is the second-leading cause of death in the United States. In 2024, a projected 234,580 new instances of lung cancer will be detected in the United States, with 125,070 deaths from the disease. Most lung malignancies are classified as either non-small cell lung cancer (NSCLC) (80%) or small cell lung cancer (14%).

On August 2023, Exact Sciences Corporation, one of the leading manufacturers of cancer screening and diagnostic tests, and Watchmaker Genomics, a provider of cutting-edge products for molecular analysis, announced a multi-year, co-exclusive agreement to develop and market TET-assisted pyridine borane sequencing (TAPS), a revolutionary DNA methylation analysis technology. To further enhance the TAPS chemistry and eventually enable cutting-edge applications like cancer screening and minimal residual disease (MRD) testing, Watchmaker will leverage its experience in developing DNA-modifying enzymes.

Geographical Outlook:

North America is expected to register highest market revenue share in DNA methylation detection technology market in 2024 driven by increasing prevalence of cancer, technological advancements in DNA methylation detection technologies. According to the Canada Cancer Society, the most often diagnosed cancer in Canada is lung and bronchus cancer (excluding non-melanoma skin tumours). Lung and bronchus cancer is expected to be detected in 32,100 Canadians by 2024. This accounts for 13% of new cancer cases in 2024. Lung and bronchus cancer will claim the lives of 20,700 Canadians. This equates to 23% of all cancer deaths in 2024.

On July 2024, FOXO Technologies Inc., a pioneer in commercializing epigenetic biomarker technology, announced the debut of its cutting-edge Bioinformatics Services, which will expedite advances in biology, biotechnology, and healthcare while also redefining the booming area of epigenetics research. FOXO’s Bioinformatics Services provide a comprehensive platform of advanced data solutions adapted to the unique requirements of clients in academia, healthcare, and pharmaceutical research.

Asia Pacific is registered the fastest growth rate during the forecasted period. This is mainly due to the increase in prevalence of cancer, rising growth of personalized medicine, and technological advancements in DNA methylation technologies. According to the Indian Council of Medical Research (ICMR), in 2022, the estimated number of new cancer cases in India was 1,461,427, with a crude incidence rate of 100.4 per 100,000 people. In India, around one in every nine persons will be diagnosed with cancer at some point in their lives. Notably, males were more likely to develop lung cancer than females, with breast cancer taking the top spot.

On December 2024, Strand Life Sciences, a renowned genomics, and bioinformatics company, has launched a blood-based test for early diagnosis of numerous malignancies. CancerSpot uses cutting-edge, globally approved methylation profiling technique to detect cancer tumor DNA fragments. The test starts with a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood.

Europe is to register a considerable market share in DNA methylation detection technology market in 2024. According to the International Agency for Research on Cancer (IARC), Europe has a disproportionately greater cancer incidence and mortality burden, as the continent has one fifth of the global cancer cases (22.4%) and cancer deaths (20.4%). On February 2024, Tagomics, a spinout from the University of Birmingham that develops a cutting-edge platform for complete illness insight and detection, has announced a GBP 6.7 million investment round. Calculus Capital led the investment, with contributions from Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, and the MEIF Proof of Concept & Early-Stage Fund. This study, sponsored by an EPSRC Healthcare Technology Challenges award, investigated techniques to discover the earliest visible changes to the genome during cancer – a process known as methylation, which turns genes on and off.

Competition Analysis:

The DNA methylation detection technology market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the DNA methylation detection technology market report are:

• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Illumina Inc.
• Agilent Technologies Inc.
• Exact Sciences Corporation
• QIAGEN N.V.
• Abcam Limited
• New England Biolabs
• Hoffmann-La Roche Ltd
• Revvity, Inc.
• Thermo Fisher Scientific, Inc.
• EpiGentek Group Inc.
• Pacific Biosciences Inc.
• Diagenode Diagnostics S.A.

Strategic Developments in DNA Methylation Detection Technology Market:

• In July 2024, Bio-Rad has announced more than 50 new ddPCR Methylation Detection Assays, which are now accessible on the company’s Digital Assays platform. These assays are meant to give more precise and reliable detection of methylation indicators, which are key tools in the investigation of early diagnosis and monitoring of various cancers.
• In February 2024, Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and an Oxford Nanopore Technologies-certified laboratory, has created a patented Targeted DNA Methylation Sequencing Service for researchers and clinical practitioners. The technique does not require amplification or bisulfite conversion, effectively removing the most common limitations of targeted methylation analysis and allowing WBL to create custom methylation panels that target hundreds to thousands of genomic loci of interest with an enrichment of 400-2300x.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Global DNA Methylation Detection Technology Market Report:

The DNA Methylation Detection Technology Market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product Outlook (Revenue, USD Million; 2022-2032)
  • Instruments
  • Software
  • Consumables
    • Kits and Assays
    • Reagents
• Technology Outlook (Revenue, USD Million; 2022-2032)
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Sequencing
    • Methyl-CpG-Binding Domain Sequencing
    • Single molecule real-time (SMRT)
    • Nanopore sequencing
    • Whole-Genome bisulfifite sequencing (WGBS)
    • Others
• Application Outlook (Revenue, USD Million; 2022-2032)
  • Clinical Research
  • Diagnostics
  • Gene Therapy

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Diagnostic Laboratories
  • Research & Academia

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the DNA Methylation Detection Technology market report